1. |
Tuasha N, Petros B. Heterogeneity of tumors in breast cancer: implications and prospects for prognosis and therapeutics. Scientifica (Cairo), 2020, 2020: 4736091. doi: 10.1155/2020/4736091.
|
2. |
DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin, 2019, 69(6): 438-451.
|
3. |
Fan M, Xia P, Clarke R, et al. Radiogenomic signatures reveal multiscale intratumour heterogeneity associated with biological functions and survival in breast cancer. Nat Commun, 2020, 11(1): 4861. doi: 10.1038/s41467-020-18703-2.
|
4. |
邵成良, 郑彬. 早产儿败血症患儿病原分布和真菌性败血症危险因素分析. 中国妇幼保健, 2022, 37(4): 654-657.
|
5. |
Alghandour R, Ebrahim MA, Ghazy H, et al. Evaluation of the diagnostic and prognostic value of Syndecan-1 in acute leukemia patients. Cureus, 2020, 12(9): e10594. doi: 10.7759/cureus.10594.
|
6. |
Valla S, Hassan N, Vitale DL, et al. Syndecan-1 depletion has a differential impact on hyaluronic acid metabolism and tumor cell behavior in luminal and triple-negative breast cancer cells. Int J Mol Sci, 2021, 22(11): 5874.
|
7. |
Miše I, Vučić M. Comparison of Syndecan-1 immunohistochemical expression in lobular and ductal breast carcinoma with nodal metastases. Anal Cell Pathol (Amst), 2018, 2018: 9432375. doi: 10.1155/2018/9432375.
|
8. |
赵晓雅, 马丛, 孙美玲, 等. 多配体蛋白聚糖-1细胞定位对人肝癌细胞侵袭的影响. 辽东学院学报(自然科学版), 2022, 29(1): 18-22.
|
9. |
Nadanaka S, Bai Y, Kitagawa H. Cleavage of Syndecan-1 promotes the proliferation of the basal-like breast cancer cell line BT-549 via Akt SUMOylation. Front Cell Dev Biol, 2021, 9: 659428. doi: 10.3389/fcell.2021.659428.
|
10. |
Kind S, Jaretzke A, Büscheck F, et al. A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer. Mol Carcinog, 2019, 58(12): 2306-2315.
|
11. |
Kim SY, Choi EJ, Yun JA, et al. Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases. Int J Med Sci, 2015, 12(2): 92-99.
|
12. |
Nikolova V, Koo CY, Ibrahim SA, et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis, 2009, 30(3): 397-407.
|
13. |
Chute C, Yang X, Meyer K, et al. Syndecan-1 induction in lung microenvironment supports the establishment of breast tumor metastases. Breast Cancer Res, 2018, 20(1): 66. doi: 10.1186/s13058-018-0995-x.
|
14. |
刘子祥, 张子艳, 周少波. Syndecan-1在恶性肿瘤浸润转移中的作用. 检验医学与临床, 2020, 17(1): 133-136.
|
15. |
Szarvas T, Reis H, Kramer G, et al. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. Hum Pathol, 2014, 45(4): 674-682.
|
16. |
Anttonen A, Leppä S, Ruotsalainen T, et al. Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer, 2003, 41(2): 171-177.
|
17. |
Szarvas T, Sevcenco S, Módos O, et al. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. Urol Oncol, 2018, 36(6): 312.e9-312.e15.
|
18. |
闻波, 陈佳伟, 王郑林, 等. 乙酰肝素酶与多配体蛋白聚糖-1在恶性肿瘤中的研究进展. 实用临床医药杂志, 2021, 25(13): 119-123.
|
19. |
刘子祥, 周少波, 张子艳, 等. 沉默SDC1通过ERK信号通路促进胆囊癌细胞的侵袭和迁移. 现代肿瘤医学, 2021, 29(21): 3726-3731.
|
20. |
Götte M, Kersting C, Ruggiero M, et al. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res, 2006, 26(1B): 621-627.
|
21. |
Nassar E, Hassan N, El-Ghonaimy EA, et al. Syndecan-1 promotes angiogenesis in triple-negative breast cancer through the prognostically relevant tissue factor pathway and additional angiogenic routes. Cancers (Basel), 2021, 13(10): 2318. doi: 10.3390/cancers13102318.
|
22. |
Pham SH, Pratt K, Okolicsanyi RK, et al. Syndecan-1 and -4 influence Wnt signaling and cell migration in human breast cancers. Biochimie, 2022, 198: 60-75.
|
23. |
Moradpoor R, Salimi M. Crosstalk between tumor cells and immune System leads to epithelial-mesenchymal transition induction and breast cancer progression. Iran Biomed J, 2021, 25(1): 1-7.
|
24. |
Gondelaud F, Ricard-Blum S. Structures and interactions of syndecans. FEBS J, 2019, 286(15): 2994-3007.
|
25. |
Dubey R, van Kerkhof P, Jordens I, et al. R-spondins engage heparan sulfate proteoglycans to potentiate WNT signaling. Elife, 2020, 9: e54469. doi: 10.7554/eLife.54469.
|
26. |
Wang Q, Yang L, Alexander C, et al. The niche factor syndecan-1 regulates the maintenance and proliferation of neural progenitor cells during mammalian cortical development. PLoS One, 2012, 7(8): e42883. doi: 10.1371/journal.pone.0042883.
|
27. |
Rajkumar T, Amritha S, Sridevi V, et al. Identification and validation of plasma biomarkers for diagnosis of breast cancer in South Asian women. Sci Rep, 2022, 12(1): 100. doi: 10.1038/s41598-021-04176-w.
|
28. |
Sheta M, Götte M. Syndecan-1 (CD138) as a pathogenesis factor and therapeutic target in breast cancer. Curr Med Chem, 2021, 28(25): 5066-5083.
|
29. |
Nguyen TL, Grizzle WE, Zhang K, et al. Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer. Am J Clin Pathol, 2013, 140(4): 468-474.
|
30. |
Scott E, Munkley J. Glycans as biomarkers in prostate cancer. Int J Mol Sci, 2019, 20(6): 1389. doi: 10.3390/ijms20061389.
|
31. |
Wang X, He J, Zhao X, et al. Syndecan-1 suppresses epithelial-mesenchymal transition and migration in human oral cancer cells. Oncol Rep, 2018, 39(4): 1835-1842.
|
32. |
Saleh ME, Gadalla R, Hassan H, et al. The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4+ T cell polarization in inflammatory and non-inflammatory breast cancer patients. PLoS One, 2019, 14(5): e0217550. doi: 10.1371/journal.pone.0217550.
|
33. |
Agere SA, Kim EY, Akhtar N, et al. Syndecans in chronic inflammatory and autoimmune diseases: Pathological insights and therapeutic opportunities. J Cell Physiol, 2018, 233(9): 6346-6358.
|
34. |
Bertrand J, Bollmann M. Soluble syndecans: biomarkers for diseases and therapeutic options. Br J Pharmacol, 2019, 176(1): 67-81.
|
35. |
De Pasquale V, Pavone LM. Heparan sulfate proteoglycan signaling in tumor microenvironment. Int J Mol Sci, 2020, 21(18): 6588. doi: 10.3390/ijms21186588.
|
36. |
Qiao W, Liu H, Guo W, et al. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis. Eur J Surg Oncol, 2019, 45(7): 1132-1137.
|
37. |
Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer, 2003, 98(3): 474-483.
|
38. |
Lim GH, Tan PH, Jara-Lazaro AR, et al. Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival. Singapore Med J, 2014, 55(9): 468-472.
|
39. |
Tiemann K, Weigel MT, Alkatout I, et al. Significance of syndecan-1 expression in ductal carcinoma in situ of the breast. Anticancer Res, 2014, 34(7): 3607-3716.
|
40. |
Conklin MW, Gangnon RE, Sprague BL, et al. Collagen alignment as a predictor of recurrence after ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev, 2018, 27(2): 138-145.
|